KuninC. M.: A Guide to Use of Antibiotics in Patients With Renal Disease. A Table of Recommended Doses and Factors Governing Serum Levels, Ann. Intern. Med.67: 151–158 (July) 1967.
2.
BulgerR. J., and PetersdorfR. G.: Antimicrobial Therapy in Patients With Renal Insufficiency, Postgrad. Med.47: 160–165 (Jan.) 1970.
3.
WagnerJ. G.: Drug Accumulation, J. Clin. Pharmacol. New Drugs7: 84–88 (Mar.-Apr.) 1967.
4.
HirschmanJ. L., and BorgsdorfL. R.: The DIAS Rounds, Drug Intell. Clin. Pharm.5: 249–251 (Aug.) 1971.
5.
GoodmanL. S., and GilmanA.: The Pharmacologic Basis of Therapeutics, ed. 4, The Macmillan Co., New York, 1970, p. 1225–1229.
6.
ReillyM.J.: Penicillin G in American Hospital Formulary Services, American Society of Hospital Pharmacists, Washington, D.C., 1962, p. 8: 12.16.
7.
WeinsteinL.: Clinical and Bacteriologic Studies of the Effect of “Massive” Doses of Penicillin G on Infections Caused by Gram-Negative Bacilli, N. E. J. Med.271: 523–525 (Sept. 10) 1964.
8.
NewP. S., and WellsC. E.: Cerebral Toxicity Associated With Massive Intravenous Penicillin Therapy, Neurology15: 1053–1058 (Nov.) 1965.
9.
OldstoneM. B. A., and NelsonE.: Central Nervous System Manifestations of Penicillin Toxicity in Man, Neurology16: 693–700 (July) 1966.
10.
BloomerH.A.: Penicillin-Induced Encephalopathy in Uremic Patients, J. Am. Med. Assoc.200: 121–123 (Apr. 10) 1967.
11.
SmithH.: Neurotoxicity and “Massive” Intravenous Therapy With Penicillin, Arch. Intern. Med.120: 47–53 (July) 1967.
12.
CohillD.F.: Central Nervous System Toxicity Secondary to Massive Doses of Penicillin G in the Treatment of Overwhelming Infections, Amer. J. Med. Sci.42: 264–272 (Nov.) 1967.
13.
BormanJ. B., and EynlL.: Neurotoxic Effects of Large Doses of Penicillin Administered Intravenously, Arch. Surg.97: 662–665 (Oct.) 1968.
ReubiF., and VorburgerC.: Renal and Extrarenal Excretion of Ampicillin in Patients With Normal and Impaired Renal Function, Pharmacol. Clin.1: 192–202 (June) 1969.
23.
MaherJ. F., and SchreinerG. E.: The Dialysis of Poisons and Drugs, Trans. Amer. Soc. Artif. Intern. Organs13: 369–393, 1967.
24.
TuanoS.P.: Comparative Blood Levels of Hetacillin, Ampicillin, and Penicillin G, N. E. J. Med.275: 635–639 (Sept. 22) 1966.
25.
RuedyJ.: The Effects of Peritoneal Dialysis on the Physiological Disposition of Oxacillin, Ampicillin, and Tetracycline in Patients With Renal Disease, Can. Med. Assoc. J.94: 257–261 (Feb. 5) 1966.
26.
KuninC. M.: Clinical Pharmacology of the New Penicillins. I. The Importance of Serum Protein Binding in Determining Antimicrobial Activity and Concentration in Serum, Clin. Pharmacol. Ther.7: 166–179 (Mar.-Apr.) 1966.
27.
PlautM.E.: Penicillin Handling in Normal and Azotemic Patients, J. Lab. Clin. Med.74: 12–18 (July) 1969.
28.
BarnettH.L.: Renal Clearance of Sodium Penicillin G, Procaine Penicillin G, and Inulin in Infants and Children, Pediatrics3: 418–422 (Apr.) 1949.
29.
HuangN.N.: Comparison of Serum Levels Following the Administration of Oral and Parenteral Preparations of Penicillin to Infants and Children of Various Age Groups, J. Pediat.42: 657–668 (June) 1953.
30.
KuninC. M., and MaxwellF. J.: Persistence of Antibiotics in Blood of Patients With Acute Renal Failure. III. Penicillin, Streptomycin, Erythromycin and Kanamycin, J. Clin. Invest.38: 1509–1519 (Sept.) 1959.
31.
HofflerD.: Ampicillin-Spiegel in Serum Und Harn bei Eingeschrankter Nierenfunktion, Deut. Med. Wochenschr.91: 206–210 (Feb. 4) 1966.
32.
MarksM. I., and EickhoffT. C.: Carbenicillin: A Clinical and Laboratory Evaluation, Ann. Intern. Med.73: 179–187 (Aug.) 1970.
33.
SmithC.B.: In Vitro Activity of Carbenicillin and Results of Treatment of Infections Due to Pseudomonas With Carbenicillin Singly and in Combination With Gentamicin, J. Infect. Dis.122 (suppl.): 514–524 (Sept.) 1970.
34.
HoffmanT. A., and BullockW. E.: Carbenicillin Therapy of Pseudomonas and Other Gram Negative Bacillary Infections, Ann. Intern. Med.72: 165–171 (Aug.) 1970.
35.
JonesR. J., and LowburyE. J. L.: Prophylaxis and Therapy for Pseudomonas aeruginosa Infections With Carbenicillin and With Gentamicin, Brit. Med. J.3: 79–82 (July 8) 1967.
36.
LowburyE. J. L.: Sensitivity of Pseudomonas aeruginosa to Antibiotics: Emergence of Strains Highly Resistant to Carbenicillin. Lancet2: 448–452 (Aug. 30) 1969.
37.
BrumfittW.: Clinical and Laboratory Studies With Carbenicillin. A New Penicillin Active Against Pseudomonas pyocyanea, Lancet1: 1289–1293 (June 17) 1967.
38.
StandifordH.C.: Laboratory and Clinical Studies of Carbenicillin Against Gram Negative Bacilli, Antimicrob. Agents Chemother.1968, 1969 p. 286–291.
39.
SmithC.B.: Use of Gentamicin in Combination With Other Antibiotics, J. Infect. Dis.119: 370–377 (Apr.-May) 1969.
40.
SonneM., and JawetzE.: Combined Action of Carbenicillin and Gentamicin on Pseudomonas aeruginosa In Vitro, Appl. Microbiol.17: 895–896 (June) 1969.
41.
EickhoffT. C.: In Vitro Effects of Carbenicillin Combined with Gentamicin or Polymyxin B Against Pseudomonas aeruginosa, Appl. Microbiol.18: 469–473 (Sept.) 1969.
42.
PhairJ.P.: In Vitro Susceptibility of Pseudomonas aeruginosa to Carbenicillin and the Combination of Carbenicillin and Gentamicin, Appl. Microbiol.18: 303–306 (Sept.) 1969.
43.
NunneryA.W.: Carbenicillin: In Vitro Synergism and Combined Therapy, J. Infect. Dis.122 (suppl.): 578–583 (Sept.) 1970.
44.
KlasterskyJ.: Antimicrobial Activity of the Carbenicillin/Gentamicin Combination Against Gram Negative Bacilli, Amer. J. Med. Sci.260: 373–380 (Dec.) 1970.
45.
McLaughlinJ. E., and ReevesD. S.: Clinical and Laboratory Evidence for Inactivation of Gentamicin by Carbenicillin, Lancet1: 261–264 (Feb.) 1971.
46.
WintersR.E.: Combined Use of Gentamicin and Carbenicillin, Ann. Intern. Med.75: 925–927 (Dec.) 1971.
47.
HoffmanT.A.: Pharmacodynamics of Carbenicillin in Hepatic and Renal Failure, Ann. Intern. Med.73: 173–178 (Aug.) 1970.
48.
RosenblattJ.E.: Mechanisms Responsible for the Blood Level Differences of Isoxazolyl Penicillins, Arch. Intern. Med.121: 345–348 (Apr.) 1968.
49.
BulgerR.J.: Effect of Uremia on Methicillin and Oxacillin Blood Levels. Excretion and Inactivation in Renal Failure and Hemodialysis, J. Am. Med. Assoc.187: 319–322 (Feb. 1) 1964.
50.
Med. Letter Drugs Ther.10: 65–66 (Aug. 23) 1968.
51.
De FeliceE. A.: Serum Levels, Urinary Recovery, and Safety of Dicloxacillin, a New Semisynthetic Penicillin, in Normal Volunteers, J. Clin. Pharmacol.7: 275–277 (Sept.-Oct.) 1967.
52.
GravenkemperC.F.: Dicloxacillin. In Vitro and Pharmacologic Comparisons With Oxacillin and Cloxacillin, Arch. Intern. Med.116: 340–345 (Sept.) 1965.
53.
NaumanP.: Laboratory and Clinical Evaluation of Dicloxacillin, Antimicrob. Agents Chemother.—7965, 1966 p. 937–946.
54.
HammerstromC.F.: Clinical, Laboratory, and Pharmacological Studies of Dicloxacillin, Antimicrob. Agents Chemother.—1966, 1967 p. 69–74.
55.
HartmanR.E.: Effect of Dicloxacillin, Oxacillin, and Nafcillin Upon Staphylococcal Population and Rate of Healing of Soft-Tissue Lesions, Antimicrob. Agents Chemother.—1966, 1967 p. 64–68.
56.
McCloskeyR. V., and HayesC.: Plasma Levels of Dicloxacillin in Oliguric Patients and the Effect of Hemodialysis, Amer. Soc. Microbiol. Abstr. Papers, 7th Intersci. Conf., Antimicrob. Agents Chemother., Chicago, Ill. (Oct. 25–27) 1967: 43 (Abstr. 97). (De Haen Drugs in Use, #U4719/9).
57.
SutherlandR., and RobinsonO. P. W.: Laboratory and Pharmacological Studies in Man With Hetacillin, Brit. Med. J.2: 805–808 (June 24) 1967.
58.
SmithJ. T., and Hamilton-MillerJ. M. T.: Hetacillin: A Chemical and Biological Comparison With Ampicillin, Chemotherapy15: 366–378, 1970.
59.
KirbyW. M. M., and KindA. C.: Clinical Pharmacology of Ampicillin and Hetacillin, Ann. N. Y. Acad. Sci.145: 291–297 (Sept. 27) 1967.
60.
TuanoS.B.: Comparative Blood Levels of Hetacillin, Ampicillin, and Penicillin G, N. E. J. Med.275: 635–639 (Sept. 22) 1966.